{"doi":"10.1037/pha0000796","title":"The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.","abstract":"50) withdrawal using the Clinical Opiate Withdrawal Scale (COWS, range = 0-48) as the primary dependent measure. Evaluating the safety of this drug combination was the secondary aim, assessed using vital signs. Before a major methodological redesign, a single participant (male, 52) with opioid use disorder completed testing. The ∼4-week inpatient study began with stabilization on oral morphine (120 mg/day). During testing, the following dose combinations of vaped cannabis (V-CB) and intranasal naloxone (IN-NLX) were tested: (a) IN-NLX 0.0 mg + V-CB 25.0 mg, (b) IN-NLX 4.0 mg + V-CB 0.0 mg, (c) IN-NLX 0.0 mg + V-CB 12.5 mg, (d) IN-NLX 4.0 mg + V-CB 12.5 mg, (e) IN-NLX 0.0 mg + V-CB 0.0 mg, and (f) IN-NLX 4.0 mg + V-CB 25.0 mg. Naloxone alone resulted in a COWS score of 22 at T+30. CB pretreatment (12.5 mg and 25.0 mg) reduced COWS scores at T+30 to 17 and 14, respectively. Active NLX and V-CB administered in combination resulted in elevated heart rate and blood pressure, though not to a greater extent than NLX alone. This study found that the addition of a cannabinoid reduced the severity of NLX-precipitated withdrawal and supported the continued investigation into combined NLX + cannabinoid formulations as overdose reversal agents. (PsycInfo Database Record (c) 2026 APA, all rights reserved).","journal":"Experimental and Clinical Psychopharmacology","year":2025,"id":572915,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9172,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT05114460"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1161193,"name":"Suky Martinez","orcid":"0000-0002-4873-8130","position":1,"is_corresponding":false},{"id":534895,"name":"Caroline A. Arout","orcid":"0000-0003-0444-6432","position":2,"is_corresponding":false},{"id":1105933,"name":"Margaret Haney","orcid":"0000-0002-1220-9528","position":3,"is_corresponding":false},{"id":1097967,"name":"Felipe Castillo","orcid":"0000-0001-7362-9043","position":4,"is_corresponding":false},{"id":1479808,"name":"Jeanne M. Manubay","orcid":null,"position":5,"is_corresponding":false},{"id":1479809,"name":"Freymon Perez","orcid":null,"position":6,"is_corresponding":false},{"id":512392,"name":"Rachel Luba","orcid":"0000-0003-3404-766X","position":7,"is_corresponding":false},{"id":900001,"name":"Sandra D. Comer","orcid":"0000-0002-8166-548X","position":8,"is_corresponding":false},{"id":1161195,"name":"Jermaine D. Jones","orcid":"0000-0003-4476-2800","position":0,"is_corresponding":true}],"reference_count":1,"raw_metadata":null,"created_at":"2026-07-19T02:57:27.876396Z","pmid":"40839512","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}